Patient characteristics
Between September 2014 and February 2017, 25 patients with HER2‐positive GC were finally enrolled in this study. The median age was 58 years (range 39–65). And the majority of patients (Patient demographics and baseline characteristics.
Other anti‐HER2 therapies: trastuzumab emtansine (T‐DM1), pertuzumab.All the patients (